Skip to main content
Fig. 2 | BMC Gastroenterology

Fig. 2

From: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis

Fig. 2

Oral corticosteroid use following tofacitinib initiation in (a) all patients and (b) in patients with oral corticosteroid use during 6-month baseline period, overall and by prior biologic history. Follow-up period was 6 months following the index date. OCS, oral corticosteroids. aPatients with a prescription for OCS during Months 1–3 and Months 4–6 of follow-up. bPatients with a prescription for OCS during Months 1–3 who did not have a prescription for OCS during Months 4–6 of follow-up. cPatients with a prescription for OCS during Months 4–6 of follow-up who did not have a prescription for OCS during Months 1–3

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us